Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.
Aged
Aged, 80 and over
Alzheimer Disease
/ diagnostic imaging
Amyloid beta-Peptides
/ metabolism
Aniline Compounds
Apolipoprotein E4
/ genetics
Brain
/ diagnostic imaging
Carbolines
Case-Control Studies
Cerebral Cortex
/ diagnostic imaging
Contrast Media
Female
Humans
Male
Middle Aged
Multiple Sclerosis
/ diagnostic imaging
Odds Ratio
Positron-Emission Tomography
Radiopharmaceuticals
Thiazoles
tau Proteins
/ metabolism
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
12
08
2019
revised:
07
01
2020
accepted:
19
01
2020
pubmed:
24
1
2020
medline:
28
7
2020
entrez:
24
1
2020
Statut:
ppublish
Résumé
To investigate β-amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from the population-based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age. AD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27-0.98], p = 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28-0.99], p = 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01-0.90], p = 0.040) were lower in MS than controls. Although AD-signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10-103.35], p = 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = -0.14 [-0.023 to -0.006], p = 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = -0.13 [-0.021 to -0.005], p = 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls. Although both β-amyloid and tau are biomarkers of cognitive aging and AD, cortical β-amyloid deposition was lower in MS than age-matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β-amyloid but not the accumulation of tau. ANN NEUROL 2020;87:556-567.
Identifiants
pubmed: 31970802
doi: 10.1002/ana.25684
pmc: PMC7078013
mid: NIHMS1558058
doi:
Substances chimiques
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
0
Amyloid beta-Peptides
0
Aniline Compounds
0
Apolipoprotein E4
0
Carbolines
0
Contrast Media
0
Radiopharmaceuticals
0
Thiazoles
0
tau Proteins
0
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
J09QS3Z3WB
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
556-567Subventions
Organisme : NIA NIH HHS
ID : R01 AG040042
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG011378
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG057547
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG044170
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG055151
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG041851
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR018898
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS097495
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
Références
Ann Neurol. 2016 Aug;80(2):247-58
pubmed: 27323247
Acta Neuropathol. 2013 Oct;126(4):461-77
pubmed: 24224195
Mult Scler. 2013 Feb;19(2):188-98
pubmed: 22736750
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
J Neural Transm (Vienna). 2011 May;118(5):747-52
pubmed: 21373761
J Neurol Sci. 1993 Jul;117(1-2):175-8
pubmed: 8410053
J Clin Invest. 2005 Sep;115(9):2423-33
pubmed: 16100572
Nat Commun. 2013;4:2030
pubmed: 23799536
Mayo Clin Proc. 1987 Apr;62(4):281-8
pubmed: 3561043
Sci Transl Med. 2016 May 11;8(338):338ra66
pubmed: 27169802
Neuroimage. 2017 Jan 1;144(Pt A):113-127
pubmed: 27577718
Ann Neurol. 2015 Nov;78(5):710-21
pubmed: 26239536
Mult Scler Relat Disord. 2019 Jan;27:232-238
pubmed: 30415025
Brain. 2018 Jan 1;141(1):271-287
pubmed: 29228201
J Alzheimers Dis. 2013;34(2):457-68
pubmed: 23234879
Nature. 1999 Jul 8;400(6740):173-7
pubmed: 10408445
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Acta Neuropathol. 1994;87(5):456-68
pubmed: 8059598
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Mult Scler. 2016 Apr;22(5):698-704
pubmed: 26447065
Eur Neurol. 1976;14(4):266-74
pubmed: 954773
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Ann Neurol. 2012 Jun;71(6):765-75
pubmed: 22488240
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Mult Scler. 2019 Jun;25(7):906-908
pubmed: 30747576
Mult Scler. 2018 May;24(6):739-749
pubmed: 28474977
Ann Neurol. 2017 Jan;81(1):58-67
pubmed: 27863444
Acta Neuropathol Commun. 2016 Jun 13;4(1):58
pubmed: 27296779
Neurology. 2019 Apr 30;92(18):e2070-e2080
pubmed: 30952794
Ann Neurol. 2008 Feb;63(2):174-83
pubmed: 17924575
Neurobiol Dis. 2004 Feb;15(1):11-20
pubmed: 14751766
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
J Neurosci. 2017 Mar 22;37(12):3192-3201
pubmed: 28213439
Neurol Clin Pract. 2014 Jun;4(3):226-230
pubmed: 25110620
Brain. 2009 May;132(Pt 5):1175-89
pubmed: 19339255
Ann Neurol. 2000 Oct;48(4):567-79
pubmed: 11026440
Brain. 2005 Nov;128(Pt 11):2705-12
pubmed: 16230320
Neurology. 2003 Nov 25;61(10):1373-7
pubmed: 14638958
Brain. 2019 Jul 1;142(7):2113-2126
pubmed: 31157360
Acta Neuropathol. 2014 Dec;128(6):755-66
pubmed: 25348064
Neurology. 2007 May 22;68(21):1800-8
pubmed: 17460158
Medicine (Baltimore). 2016 Mar;95(10):e3056
pubmed: 26962833
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
Alzheimers Dement. 2012 May;8(3):219-26
pubmed: 22546354
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Mol Neurodegener. 2018 Jul 24;13(1):38
pubmed: 30041668
Brain. 2015 May;138(Pt 5):1370-81
pubmed: 25805643
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808
Neurology. 2019 Jul 2;93(1):e29-e39
pubmed: 31147421